Affordable Access

Publisher Website

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

Authors
Journal
New England Journal of Medicine
0028-4793
Publisher
New England Journal of Medicine
Publication Date
Volume
361
Issue
8
Identifiers
DOI: 10.1056/nejmoa0810818
Keywords
  • Antineoplastic Agents
  • Hormonal/Administration & Dosage
  • Antineoplastic Agents
  • Hormonal/Adverse Effects
  • Aromatase Inhibitors/Administration & Dosage
  • Aromatase Inhibitors/Adverse Effects
  • Breast Neoplasms/Drug Therapy
  • Chemotherapy
  • Adjuvant
  • Disease-Free Survival
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Fractures
  • Bone/Epidemiology
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Neoplasm Recurrence
  • Local/Prevention & Control
  • Nitriles/Administration & Dosage
  • Nitriles/Adverse Effects
  • Postmenopause
  • Proportional Hazards Models
  • Tamoxifen/Administration & Dosage
  • Tamoxifen/Adverse Effects
  • Triazoles/Administration & Dosage
  • Triazoles/Adverse Effects
Disciplines
  • Biology
  • Medicine

Abstract

BACKGROUND: The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer. It is unknown whether sequential treatment with tamoxifen and letrozole is superior to letrozole therapy alone. METHODS: In this randomized, phase 3, double-blind trial of the treatment of hormone-receptor-positive breast cancer in postmenopausal women, we randomly assigned women to receive 5 years of tamoxifen monotherapy, 5 years of letrozole monotherapy, or 2 years of treatment with one agent followed by 3 years of treatment with the other. We compared the sequential treatments with letrozole monotherapy among 6182 women and also report a protocol-specified updated analysis of letrozole versus tamoxifen monotherapy in 4922 women. RESULTS: At a median follow-up of 71 months after randomization, disease-free survival was not significantly improved with either sequential treatment as compared with letrozole alone (hazard ratio for tamoxifen followed by letrozole, 1.05; 99% confidence interval [CI], 0.84 to 1.32; hazard ratio for letrozole followed by tamoxifen, 0.96; 99% CI, 0.76 to 1.21). There were more early relapses among women who were assigned to tamoxifen followed by letrozole than among those who were assigned to letrozole alone. The updated analysis of monotherapy showed that there was a nonsignificant difference in overall survival between women assigned to treatment with letrozole and those assigned to treatment with tamoxifen (hazard ratio for letrozole, 0.87; 95% CI, 0.75 to 1.02; P=0.08). The rate of adverse events was as expected on the basis of previous reports of letrozole and tamoxifen therapy. CONCLUSIONS: Among postmenopausal women with endocrine-responsive breast cancer, sequential treatment with letrozole and tamoxifen, as compared with letrozole monotherapy, did not improve disease-free survival. The difference in overall survival with letrozole monotherapy and tamoxifen monotherapy was not statistically significant. (ClinicalTrials.gov number, NCT00004205.)

There are no comments yet on this publication. Be the first to share your thoughts.